



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/118509/2013

European Medicines Agency decision

P/0045/2013

of 1 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for enzastaurin (hydrochloride) (EMEA-001033-PIP02-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0045/2013

of 1 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for enzastaurin (hydrochloride) (EMA-001033-PIP02-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Eli Lilly & Company Limited on 3 April 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 January 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for enzastaurin (hydrochloride), tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for enzastaurin (hydrochloride), tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for enzastaurin (hydrochloride), tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Eli Lilly & Company Limited, Research Center, Erl Wood Manor, Sunninghill Road, GU20 6PH Windlesham, United Kingdom.

Done at London, 1 March 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/751087/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001033-PIP02-11

Scope of the application

Active substance(s):

Enzastaurin (hydrochloride)

Condition(s):

Treatment of diffuse large B-cell lymphoma

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Eli Lilly & Company Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Eli Lilly & Company Limited submitted for agreement to the European Medicines Agency on 3 April 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 May 2012.

Supplementary information was provided by the applicant on 22 October 2012. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 11 January 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

Waiver

1.1. Condition: Treatment of diffuse large B-cell lymphoma

The waiver applies to:

The request for the waiver applied to:

- The paediatric population from birth to less than 6 months years of age
- for tablet for oral use
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of diffuse large B-cell lymphoma

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with high-risk B-cell non-Hodgkin lymphoma in remission after front-line treatment

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1: Generation of data to support an oral suspension prepared from the tablet
Non-clinical	1	Measure 2: Immunohistochemistry molecular subtyping and somatic mutation profiling for correlative analyses and biomarker development
Clinical	1	Measure 3: Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of enzastaurin in children from 6 months to less than 18 years of age with mature B-cell lymphoma in first remission identified by a biomarker

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes